echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Evaluatepharma: the sky high selling price of Gilead sovaldi is not a special case, but a trend

    Evaluatepharma: the sky high selling price of Gilead sovaldi is not a special case, but a trend

    • Last Update: 2014-09-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: biodiscovery 2014-09-28 geeled star hepatitis C drug sovaldi achieved an amazing $5.8 billion in sales in the first half of 2014 The drug was launched in the United States in December 2013, and has become the focus of the industry since its birth The pricing of its $84000 / course (1000 / tablet) has also been controversial But a new report by evaluatepharma, a global pharmaceutical market forecasting agency, shows that the sky high selling price of sovaldi is not a special case, but a trend that has lasted for nearly five years in the pharmaceutical industry According to evaluatepharma, the average money earned by the top 100 drugs in the United States per patient has increased from $1260 in 2010 to $9400 today The reason for this change is that the average number of patients using the top 100 drugs has decreased from 690000 in 2010 to 146000 today, a total reduction of 79% Part of the reason for this shift may be that the pharmaceutical industry is moving towards a "patent cliff." Patent expiration will have a huge impact on the company These years are the peak of patent invalidation Pfizer's cholesterol lowering drug Lipitor, Sanofi's blood thinner Plavix and Takeda's diabetes drug Actos lost patent protection in 2011-2012 In addition, FDA regulation is more strict, and drug companies spend more time and money on new drug research and development, which is another reason for the high selling price of drugs with small audience According to the evaluation Pharma report, in 2010, only 23 of the top 100 drugs were used to treat diseases with a population of 100000 or less, but this year it has increased to 41 In contrast, the number of diseases used to treat more than 500000 patients in the top 100 drugs has changed from 55 in 2010 to 35 The U.S medical payment system allows the long-term monopoly of "high priced drugs", but it will also punish those high priced drugs whose prices do not match the efficacy Sanofi is an example In 2012, the FDA approved the company's zaltrap as a second-line treatment for colorectal cancer Like many new anticancer drugs, the drug is not cheap, costing $9600 a month But not long after, three doctors at the memorial Sloan Caitlin cancer center wrote in the New York Times that the high price of zaltrap was not commensurate with the small expected return, and that the center had removed zaltrap from the drug list Sanofi initially defended zaltrap's price, then was forced to back down to 50% However, there are also some companies whose drugs can still be sold at a high price in the face of generic competition, such as Roche's cancer drug Herceptin, rituxan, celgene's blood cancer drug Revlimid, etc., because the therapeutic effect of these drugs on patients is worth it Both the private and the institutions are complaining about the trend of "high price medicine", but if there is no organization to intervene in this situation, the trend will last for a long time Of course, the buyer may start to analyze the payment return benefits of these "priceless drugs" and then exclude those drugs that are not qualified enough In this case, if pharmaceutical companies want to maintain their high prices, they need to ensure the real therapeutic effect of drugs.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.